PAREXEL International Co. (PRXL) Now Covered by Mizuho

Mizuho began coverage on shares of PAREXEL International Co. (NASDAQ:PRXL) in a research note published on Thursday morning. The brokerage issued a neutral rating and a $86.00 target price on the medical research company’s stock.

PRXL has been the topic of a number of other research reports. Evercore ISI lowered shares of PAREXEL International from a buy rating to a hold rating and set a $71.50 target price on the stock. in a research report on Wednesday, January 4th. Deutsche Bank AG lowered shares of PAREXEL International from a hold rating to a sell rating and decreased their target price for the stock from $66.00 to $53.00 in a research report on Friday, February 3rd. Citigroup Inc lowered shares of PAREXEL International from a buy rating to a neutral rating in a research report on Friday, February 3rd. Goldman Sachs Group Inc lowered shares of PAREXEL International from a neutral rating to a sell rating in a research report on Friday, December 16th. Finally, Zacks Investment Research lowered shares of PAREXEL International from a buy rating to a hold rating in a report on Tuesday, February 7th. Three research analysts have rated the stock with a sell rating and twelve have given a hold rating to the stock. PAREXEL International presently has an average rating of Hold and a consensus target price of $68.95.

Shares of PAREXEL International (NASDAQ:PRXL) traded up 1.25% during trading on Thursday, reaching $62.58. The company had a trading volume of 506,445 shares. The company has a market capitalization of $3.19 billion, a PE ratio of 22.21 and a beta of 0.82. The stock’s 50-day moving average price is $62.92 and its 200-day moving average price is $64.15. PAREXEL International has a 52 week low of $51.16 and a 52 week high of $72.32.

TRADEMARK VIOLATION WARNING: “PAREXEL International Co. (PRXL) Now Covered by Mizuho” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/04/20/parexel-international-co-prxl-coverage-initiated-by-analysts-at-mizuho-updated-updated.html.

In related news, SVP Sybrand Pretorius sold 8,050 shares of PAREXEL International stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $65.12, for a total transaction of $524,216.00. Following the sale, the senior vice president now owns 9,950 shares of the company’s stock, valued at approximately $647,944. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gadi Saarony sold 2,325 shares of PAREXEL International stock in a transaction on Thursday, February 9th. The stock was sold at an average price of $64.54, for a total transaction of $150,055.50. Following the sale, the insider now directly owns 14,208 shares in the company, valued at approximately $916,984.32. The disclosure for this sale can be found here. Insiders own 2.90% of the company’s stock.

Several large investors have recently added to or reduced their stakes in PRXL. Clinton Group Inc. increased its stake in PAREXEL International by 775.2% in the third quarter. Clinton Group Inc. now owns 38,003 shares of the medical research company’s stock valued at $2,639,000 after buying an additional 33,661 shares during the last quarter. Zebra Capital Management LLC bought a new stake in PAREXEL International during the fourth quarter valued at $1,057,000. BTIM Corp. bought a new stake in PAREXEL International during the third quarter valued at $14,463,000. Emerald Acquisition Ltd. increased its stake in PAREXEL International by 4.8% in the third quarter. Emerald Acquisition Ltd. now owns 292,632 shares of the medical research company’s stock valued at $20,323,000 after buying an additional 13,367 shares during the last quarter. Finally, UBS Group AG increased its stake in PAREXEL International by 2.0% in the third quarter. UBS Group AG now owns 3,131,814 shares of the medical research company’s stock valued at $217,504,000 after buying an additional 61,474 shares during the last quarter. 91.44% of the stock is owned by institutional investors.

About PAREXEL International

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

5 Day Chart for NASDAQ:PRXL

Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply